{"id":"NCT01628120","sponsor":"Pfizer","briefTitle":"A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin","officialTitle":"A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05-31","primaryCompletion":"2015-02-13","completion":"2015-02-13","firstPosted":"2012-06-26","resultsPosted":"2018-07-19","lastUpdate":"2019-03-18"},"enrollment":170,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Renal Failure Requiring Hemodialysis"],"interventions":[{"type":"BIOLOGICAL","name":"Epoetin Hospira","otherNames":["ESA","Erythropoetin Stimulation Agents"]}],"arms":[{"label":"Epoetin Hospira","type":"EXPERIMENTAL"}],"summary":"To determine the long term safety in treatment-emergent adverse events (TEAEs) of SC administration of Epoetin Hospira for maintenance of target hemoglobin (Hgb) levels in patients treated for anemia associated with chronic renal failure and on hemodialysis.","primaryOutcome":{"measure":"Percentage of Participants With Treatment Emergent Adverse Events (AEs): Week 1","timeFrame":"Up through 7 days after first dose of study drug (Week 1)","effectByArm":[{"arm":"Epoetin Hospira","deltaMin":17.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":115,"countries":["United States"]},"refs":{"pmids":["32734207"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":59,"n":170},"commonTop":["Muscle spasms","Nausea","Headache","Diarrhoea","Dyspnoea"]}}